AI Article Synopsis
- - Atezolizumab and bevacizumab are being investigated as a combined treatment option for patients with both hepatocellular carcinoma (a type of liver cancer) and gastric adenocarcinoma (a type of stomach cancer).
- - This combination therapy may offer a new approach to improving treatment outcomes for individuals dealing with both cancers at the same time.
- - Research into this therapy aims to explore its effectiveness and potential benefits for patients facing these challenging conditions.
Article Abstract
Atezolizumab and bevacizumab combination therapy might be one of the treatment options for hepatocellular carcinoma concurrent with gastric adenocarcinoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483490 | PMC |
| http://dx.doi.org/10.1002/ccr3.7875 | DOI Listing |
Publication Analysis
Top Keywords
hepatocellular carcinoma
8
gastric adenocarcinoma
8
atezolizumab bevacizumab
8
carcinoma gastric
4
adenocarcinoma treated
4
treated atezolizumab
4
bevacizumab atezolizumab
4
bevacizumab combination
4
combination therapy
4
therapy treatment
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!